Enhanc3D Genomics Appoints Hazel Jones As CEO

On May 15, 2024, Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, announced the appointment of Hazel Jones, PhD, as Chief Executive Officer, after a successful six-month tenure as interim CEO and COO. As COO and interim CEO, Dr. Jones has overseen the company's global business operations and held responsibility for executing its strategic vision for commercial and academic partnerships. She has played a leading role in transitioning the company's 3D genomics platform from development to practical application in R&D. With over a decade of senior leadership experience in oncology research, Dr. Jones brings expertise in all phases of drug development, from target validation to clinical development, driving operational change to advance disease diagnosis and treatments. Prior to joining Enhanc3D Genomics as COO in November 20231, Dr. Jones held various roles within AstraZeneca, including Executive Product Director of Clinical Data, and Head of Business Planning and Operations in Oncology R&D. She was also previously Head of Combination Therapies at Cancer Research UK. Dr. Jones holds a BSc in Pharmacology and completed her PhD in Biochemistry at the University of Leeds.

Login Or Register To Read Full Story